title: Temporal Evolution and Dose-Volume Histogram Predictors of Visual Acuity After Proton Beam Radiation Therapy of Uveal Melanoma.
abstract: To perform an in-depth temporal analysis of visual acuity (VA) outcomes after proton beam radiation therapy (PBRT) in a large, uniformly treated cohort of uveal melanoma (UM) patients, to determine trends in VA evolution depending on pretreatment and temporally defined posttreatment VA measurements; and to investigate the relevance of specific patient, tumor and dose-volume parameters to posttreatment vision loss.
  
  
  
  Uveal melanoma patients receiving PBRT were identified from a prospectively maintained database. Included patients (n=645) received 56 GyE in 4 fractions, had pretreatment best corrected VA (BCVA) in the affected eye of count fingers (CF) or better, with posttreatment VA assessment at specified post-PBRT time point(s). Patients were grouped according to the pretreatment BCVA into favorable (≥20/40) or unfavorable (20/50-20/400) and poor (CF) strata. Temporal analysis of BCVA changes was described, and univariate and forward stepwise multivariate logistic regression analyses were performed to identify predictors for VA loss.
  
  
  
  Median VA follow-up was 53 months (range, 3-213 months). At 60-month follow up, among evaluable treated eyes with favorable pretreatment BCVA, 45% retained BCVA ≥20/40, whereas among evaluable treated eyes with initially unfavorable/poor BCVA, 21% had vision ≥20/100. Among those with a favorable initial BCVA, attaining BCVA of ≥20/40 at any posttreatment time point was associated with subsequent maintenance of excellent BCVA. Multivariate analysis identified volume of the macula receiving 28GyE (P<.0001) and optic nerve (P=.0004) as independent dose-volume histogram predictors of 48-month post-PBRT vision loss among initially favorable treated eyes.
  
  
  
  Approximately half of PBRT-treated UM eyes with excellent pretreatment BCVA assessed at 5 years after treatment will retain excellent long-term vision. 28GyE macula and optic nerve dose-volume histogram parameters allow for rational treatment planning optimization that may lead to improved visual outcomes. The detailed temporal analysis with intermediate as well as long-term functional prognosis, and the relationship of outcomes with clinical and treatment planning parameters, is critical for informed care of UM patients before and after PBRT.
authors.affiliation: Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
authors.forename: Alexei L
authors.initials: AL
authors.lastname: Polishchuk
authors.affiliation: Department of Radiation Oncology, University of California, San Francisco, San Francisco, California. Electronic address: Kavita.Mishra@ucsf.edu.
authors.forename: Kavita K
authors.initials: KK
authors.lastname: Mishra
authors.affiliation: Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
authors.forename: Vivian
authors.initials: V
authors.lastname: Weinberg
authors.affiliation: Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
authors.forename: Inder K
authors.initials: IK
authors.lastname: Daftari
authors.affiliation: Tumori Foundation, San Francisco, California.
authors.forename: Jacqueline M
authors.initials: JM
authors.lastname: Nguyen
authors.affiliation: Tumori Foundation, San Francisco, California.
authors.forename: Tia B
authors.initials: TB
authors.lastname: Cole
authors.affiliation: Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
authors.forename: Jeanne M
authors.initials: JM
authors.lastname: Quivey
authors.affiliation: Department of Radiation Oncology, University of California, San Francisco, San Francisco, California.
authors.forename: Theodore L
authors.initials: TL
authors.lastname: Phillips
authors.affiliation: Tumori Foundation, San Francisco, California.
authors.forename: Devron H
authors.initials: DH
authors.lastname: Char
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019583:Dose Fractionation, Radiation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008266:Macula Lutea / Q000528:radiation effects; D008297:Male; D008545:Melanoma / Q000532:radiotherapy*; D008875:Middle Aged; D009900:Optic Nerve / Q000528:radiation effects; D059351:Organ Sparing Treatments / Q000379:methods*; D061766:Proton Therapy / Q000009:adverse effects / Q000379:methods*; D011879:Radiotherapy Dosage; D012044:Regression Analysis; D013997:Time Factors; D016896:Treatment Outcome; D014604:Uveal Neoplasms / Q000532:radiotherapy*; D014786:Vision Disorders / Q000209:etiology / Q000517:prevention & control; D014792:Visual Acuity / Q000502:physiology / Q000528:radiation effects*